Investigating a possible link between antiseptic treatment and the increased occurrence of daptomycin-resistant Staphylococcus aureus.


Journal

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 07 03 2023
revised: 26 05 2023
accepted: 06 06 2023
medline: 26 9 2023
pubmed: 16 6 2023
entrez: 15 6 2023
Statut: ppublish

Résumé

Because of a steady increase in the detection of daptomycin-resistant (DAP-R) Staphylococcus aureus at three medical centres in Cologne, Germany, molecular surveillance was established from June 2016 to June 2018 to investigate the causes of the emergence and spread of respective isolates. Seventy-five S. aureus isolates, both DAP-R and DAP-susceptible, were collected from 42 patients for further analysis. Broth microdilution was used to determine the MICs for DAP and polyhexamethylene biguanide/polyhexanide (PHMB). To investigate the effect of PHMB on the development of DAP resistance, we performed selection experiments with PHMB. All isolates studied were subjected to whole-genome sequencing. Epidemiological, clinical, microbiological and molecular data were analysed comparatively. Acquisition of DAP resistance was mainly observed in patients with acute and chronic wounds (40/42, 96.2%) treated with antiseptic (32/42, 76.2%) rather than systemic antibiotic therapy using DAP or vancomycin (7/42, 16.7%). DAP-R S. aureus had a diverse genetic background; however, within individual patients, isolates were closely related. At least three potential transmission events were detected. Most DAP-R isolates had concomitant elevated MICs for PHMB (50/54, 92.6%), and in vitro selection experiments confirmed that PHMB treatment is capable of generating DAP resistance. DAP resistance could be linked to 12 different polymorphisms in the mprF gene in the majority of clinical isolates (52/54, 96.3%) as well as in all in vitro selected strains. DAP resistance in S. aureus can occur independently of prior antibiotic therapy and can be selected by PHMB. Therefore, wound treatment with PHMB may trigger individual resistance development associated with gain-of-function mutations in the mprF gene.

Identifiants

pubmed: 37321393
pii: S1198-743X(23)00282-3
doi: 10.1016/j.cmi.2023.06.007
pii:
doi:

Substances chimiques

Daptomycin NWQ5N31VKK
Anti-Infective Agents, Local 0
Anti-Bacterial Agents 0
Bacterial Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1334.e1-1334.e6

Informations de copyright

Copyright © 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Auteurs

Andreas F Wendel (AF)

Institute of Hygiene, Cologne Merheim Medical Centre, University Hospital of Witten/Herdecke, Cologne, Germany; Division of Hygiene and Environmental Medicine, Department of Human Medicine, Faculty of Health, Witten/Herdecke University, Witten, Germany.

Robin Otchwemah (R)

Institute of Hygiene, Cologne Merheim Medical Centre, University Hospital of Witten/Herdecke, Cologne, Germany; Division of Hygiene and Environmental Medicine, Department of Human Medicine, Faculty of Health, Witten/Herdecke University, Witten, Germany.

Franziska Layer-Nicolaou (F)

Robert Koch Institute, Department of Infectious Diseases, Division 'Nosocomial Pathogens and Antibiotic Resistances', National Reference Centre for Staphylococci and Enterococci, Wernigerode, Germany.

Frauke Mattner (F)

Institute of Hygiene, Cologne Merheim Medical Centre, University Hospital of Witten/Herdecke, Cologne, Germany; Division of Hygiene and Environmental Medicine, Department of Human Medicine, Faculty of Health, Witten/Herdecke University, Witten, Germany.

Carlos J Tellez-Castillo (CJ)

Department of Clinical Microbiology, MVZ Synlab Leverkusen GmbH, Köln-Merheim, Germany.

Robert Skov (R)

Department of Clinical Microbiology, MVZ Synlab Leverkusen GmbH, Köln-Merheim, Germany.

Henrik Oberländer (H)

Department of Plastic Surgery, Hand Surgery, Burn Centre, Cologne Merheim Medical Centre, University Hospital of Witten/Herdecke, Cologne, Germany.

Guido Werner (G)

Robert Koch Institute, Department of Infectious Diseases, Division 'Nosocomial Pathogens and Antibiotic Resistances', National Reference Centre for Staphylococci and Enterococci, Wernigerode, Germany.

Birgit Strommenger (B)

Robert Koch Institute, Department of Infectious Diseases, Division 'Nosocomial Pathogens and Antibiotic Resistances', National Reference Centre for Staphylococci and Enterococci, Wernigerode, Germany. Electronic address: strommengerb@rki.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH